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CLINICAL INVESTIGATION
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Heme biosynthesis in uremic patients on CAPD or hemodialysis. We
have analyzed some parameters of porphyrin metabolism in 60 patients
with end-stage renal failure, 20 of them on CAPD and the remaining on
HD. In comparison with 56 control subjects, both groups of patients
showed the three following findings: low erythrocyte aminolevulinate
dehydrase activity, inhibition ability for the activity of this enzyme
when their plasma was incubated in vitro with normal erythrocytes, and
increased plasma porphyrin levels. Like anemia, these abnormalities
were more remarkable in patients on HD who also exhibited increased
erythrocyte protoporphynn levels and compensatory porphobilinogen
deaminase activities. Mean weekly porphyrin removal through dialy-
sate was higher in CAPD (90.8 g) than in HD patients (30.4 tg).
Dialysate and plasma porphyrins were correlated in both circumstances
(r = 0.714, P < 0.01 and r = 0.637, P < 0.05, respectively). The less
pronounced porphyrin abnormalities found in CAPD patients with
respect to HD patients may be due to the more efficient capability of
peritoneal dialysis for removing from plasma protein-bound substances,
as porphyrins and inhibitors of aminolevulinate dehydrase or other
enzymes involved in erythropoiesis. Since no close relationship was
found between these abnormalities of porphyrin metabolism and he-
matocrit values, the anemia of uremia cannot be merely considered as
a direct consequence of altered heme biosynthetic pathway.
The anemia of chronic renal failure (CRF) is multifactonal.
The main mechanisms traditionally considered are: absolute or
relative erythropoietin (EPO) deficiency, shortened red blood
cell survival, repeated bleeding and presence of erythropoietic
inhibitors [1].
Several abnormalities of the heme biosynthetic pathway have
been observed in patients with CRF [2—7]. Most studies have
been performed in patients on hemodialysis (HD) or in non-
dialyzed patients, lacking references about patients treated with
continuous ambulatory pentoneal dialysis (CAPD). This thera-
peutic option is usually associated with less anemia than HD [8,
9]. This finding is probably due to the fact that CAPD more
efficiently removes middle molecules, high-molecular-weight
albumin-bound uremic toxins, and other substances, such as
polyamines, with inhibitory effects on erythropoiesis [10—12].
The aim of the present study was to assess and compare some
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parameters of heme synthesis in CRF on HD and CAPD, under
the hypothesis that the abnormalities of porphyrin metabolism
might be related to the pathogenesis of renal anemia.
Methods
Patients
We have studied porphyrin metabolism in 60 patients with
end-stage renal failure, 20 of them on CAPD and 40 on HD
(Table 1), this being in both circumstances the only dialysis
technique used. All CAPD patients had four exchanges daily of
2 liters of dialysate (1.5 to 4.25% dextrose). The HD procedure
was performed three times a week (4 hr/session), using cu-
prophan membranes and acetate bath. No patient had been
treated with recombinant human EPO.
Fifty-two healthy subjects (16 females, 36 males; mean age 50
18 years, range 17 to 76 years) formed the control group.
Methods
The activity of aminolevulinic acid dehydrase (EC 4.2.1.24)
(ALA-D) in red blood cells (RBC) was determined by the
European Standardized Method [13]. The restored enzyme
activity was measured according to Fujita et al [14] after
addition of zinc and dithiothreitol (D) to the incubation
media.
For the assessment of ALA-D inhibition ability of uremic
plasma, normal RBCs were washed twice with isotonic KC1
solution and preincubated for 20 minutes at 37°C with equal
amounts of plasma samples from 25 HD and 16 CAPD patients.
ALA-D inhibition was expressed as a percentage of the control
values obtained after preincubation of normal RBCs with their
own plasma.
Uremic plasma inhibition ability for the activity of normal
erythrocyte ALA-D was also measured after deproteinization
of HD plasma samples with proteinase K (50 g/dl), by heating
at 60°C during 60 minutes, and by ultrafiltration through a
micropartition system fitted with a YMT membrane (Amicon,
Danvers, Massachusetts, USA) [15]. Non-deproteinized plasma
samples from HD patients and normal subjects were used as
controls.
ALA-D activities from 10 normal subjects were measured
after preincubation of their RBCs with urea (100 mg/dl and 200
mg/dl) for 15 or 30 minutes.
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Table 1. Clinical and biochemical data of patients on continuous





Age years 57 12 51 16 NS
Sex (%)
female 11(55) 23 (58) NS
male 9 (45) 17 (42) NS
Period on dialysis months 21(3—177) 55 (5—180) <0.01
(range)
Hematocrit % 31.2 7.2 27.41 5.14 <0.05
Residual renal function 1.72 2.47 6.45 3.25 <0.001
mi/mm
Albumin gIdi 3.6 0.5 3.6 0.5 NS
Zinc pg/dl 80.1 16.7 47.97 11.2 <0.001
Serum ferritin pg/iiter 77 (23.5—707.6) 133 (11—875) NS
(range)N 19 10
Aluminum ng/ml (range) 83 (9—368) 124.2 (73.4—313.8) NSN 7 9
Data are mean SD or median (range). NS is not significant.
The activity of porphobilinogen deaminase (EC 4.3.1.8) in
RBCs was measured as described by Anderson and Desnick
[16].
Plasma, erythrocyte and dialysate porphyrin concentrations
were quantitated by the fluorometric micromethod described by
Piomelli [17]. The peritoneal dialysate fluid sample was ob-
tained from the 4.25% dextrose nocturnal exchange. Urinary
porphynns were measured according to Westerlund, Pudek and
Schreiber [18]. The erythrocyte zinc-protoporphyrin/free-pro-
toporphynn ratio was estimated by fluorometric scanning after
ethanol extraction [19]. Individual carboxylated porphyrins in
urine and dialysate were separated by thin layer chromatogra-
phy of their methyl esters [20].
Serum albumin was measured by cellulose acetate electro-
phoresis (Olympus HYTE-600 Automatic). Plasma zinc and
aluminium levels were determined by atomic absorption spec-
trophotometry (Perkin-Elmer- 1100 and -5000 with a graphite
furnace, respectively), and serum ferritin was assessed by an
immunoenzymetric assay (TandemREFerritin, Hybritech,
Liege, Belgium).
Statistics
Differences were analyzed by parametric (Student t and
ANOVA tests) and non-parametric (Mann-Whitney and Fried-
man) methods according to the normal or skewed distribution of
the parameters, respectively. Pearson's correlation coefficient
(r) was computed to test the association between pairs of
variables. The SPSS/PC+ (Chicago, Illinois, USA) statistical
program was used. The null hypothesis was rejected when P <
0.05.
Results
Patients with CRF (Table 2) on HD showed decreased
erythrocyte activity of ALA-D, compensatory hyperactivity of
PBG-D, and increased plasma and erythrocyte porphyrin con-
centrations; those under CAPD treatment exhibited erythrocyte
ALA-D activities which were significantly lower than those in
controls, but higher than those in HD patients. Similarly,
plasma porphyrins were increased twofold in these patients but
Table 2. Heme pathway parameters of controls, and patients on
continuous ambulatory peritoneal dialysis (CAPD) and
hemodialysis (HD)
Controls CAPD HD
ALA-D .unol ALA/liter 31.9 7.6 22.5 5•7a,b 13.3 6.8a
RBC mm
Restored ALA-D mol 65.1 10.2 47.6 8.4a 55.1 l4.7a
ALA/liter RBC mm
PBG-D nmoi URO/mi 31.2 8.0 36.2 88b 63.7 25.3a
RBC hr









Abbreviations are: ALA-D, aminolevulinate dehydratase; PBG-D,
porphobilinogen deaminase; PROTO, protoporphyrin. Data are ex-
pressed as mean SD.
P < 0.01 vs. control groupb P < 0.01 vs. HD group.
did not reach the values observed in HD. Erythrocyte PBG-D
activity and protoporphyrin levels were not modified in CAPD
patients, and the zinc protoporphyrin/free protoporphyrin ratio
remained within normal values.
If we consider CRF patients and control subjects as a whole,
erythrocyte ALA-D activity weakly correlated both with
plasma porphyrins (r = —0.618, P < 0.01) and with hematocrit
values (r = 0.608, P < 0.01). However, the intragroup correla-
tions between ALA-D and hematological parameters were null.
ALA-D values did not correlate either with creatinine clear-
ance, time on dialysis, or serum aluminum levels. Serum zinc
levels showed weak correlations with erythrocyte ALA-D (r =
0.430, P < 0.05) and with plasma porphynns (r = —0.454, P <
0.05).
Addition of zinc and D1'T to the incubation media (restored
ALA-D) produced a partial recovery of the enzyme activity in
erythrocytes from both HD and CAPD patients (Table 2);
however, in both circumstances the values were lower than
those in controls.
In vitro, plasma from CRF patients induced an inhibitory
effect on normal erythrocyte ALA-D activity. This effect was
greater (P < 0.001) for HD samples (16.8 6.8%) than for
CAPD ones (9.7 5.2%). Such inhibitory ability of HD plasma
was almost completely abolished (0.65 0.9%) by previous
deproteinization with an ultrafiltration system, and it was
significantly (P < 0.05) reduced when other deproteinization
techniques, such as proteinase K (9.7 5.3%) or heating (9.9
4.5%), were used. Addition of different concentrations of urea
to the preincubation media did not modify ALA-D activity
(Table 3).
Dialysate from CAPD patients contained 0.63 0.18 g/liter of
proteins and 1.19 1.48 pg/liter of porphyrins (mean SD).
Since mean daily peritoneal drainage of CAPD was 10.9 liter,
the total mean weekly protein and porphyrin losses through
dialysate were 48.1 g and 90.8 pjg, respectively. The pattern of
dialysate individual carboxylate porphyrins was as follows:
uroporphyrin 80.1%, hepta- 7.3%, penta- 0.2%, and copropor-
phyrin 12.2%. Dialysate and plasma porphyrin levels correlated(r = 0.714, P < 0.01).
In ten HD patients, porphyrin levels were measured in
lyophilized samples of dialysate obtained two hours after the
222 Fontanellas et a!: Heme biosynthesis in uremic patients
Table 3. Lack of effect of in vitro urea addition on erythrocyte ALA-




0 miii 29.5 7.3 30.5 t 7,9 28.5 7.7
15 mm 34.2 8.3 35.7 8.1 34.3 5.4
30mm 34.8 4.8 34.1 3.1 32.2 7.8
Data are expressed in unol ALA/liter RBC/min (mean SD).
No significant differences were observed.
beginning of the every dialysis session of the week. The
calculated mean weekly porphyrin removal was 30.4 7.3 pg.
The profile of dialysate porphyrins revealed a low percentage of
coproporphyrin (15.8%), traces of penta- (0.5%) and hexacar-
boxylated porphyrins (0.1%), and predominance of highly car-
boxylated porphyrins (uroporphyrin 69.3% and heptaporphyrin
14.3%). Again, dialysate and plasma porphyrin concentrations
were weakly correlated (r = 0.637, P < 0.05).
Seven patients on CAPD and eight on HD had some residual
urine output. Their daily urinary porphyrin excretion widely
varied, ranging from I to 51 zg, with an abnormal pattern of
predominance of highly carboxylated porphyrins and low per-
centual values of coproporphynn in both cases.
Discussion
The findings in our HD patients confirm previous reports
[2—71 revealing some abnormalities of porphyrin metabolism in
CRF: decreased erythrocyte ALA-D activity with compensa-
tory PBG-D hyperactivity, and increased plasma and erythro-
cyte porphyrins.
Our uremic patients on CAPD treatment exhibited less ex-
tended and less pronounced abnormalities of heme metabolism
than those detected in patients on HD. These differences might
be at least in part related to the lesser degree of anemia found in
our CAPD patients. However, the relationship between eryth-
rocyte ALA-D activities and hematocrit data was not markedly
close. A close reverse relationship between these two parame-
ters should not be expected, since ALA-D is not a rate-limiting
enzyme. The low values of erythrocyte ALA-D observed in our
CRF patients may be the consequence of either a decreased
synthesis of the enzyme or an inhibition of its activity.
The levels of restored ALA-D activity may be considered to
represent the full expression of the enzyme activity present in
RBCs. Therefore, the non-complete recovery of ALA-D activ-
ity after addition of Zn and Dfl' (restored ALA-D), suggests
that, besides an inhibition of enzyme catalytic activity, the
enzyme synthesis is also partially defective in CRF. Quantita-
tion of the immunoreactive enzyme protein would clarify this
hypothesis.
The presence of a protein, or protein-bound, ALA-D inhibi-
tor in plasma of CRF patients contributes to explain the
decreased activity of erythrocyte ALA-D. The inhibitory ca-
pacity of plasma from CAPD patients was less pronounced than
that detected in plasma from HD patients, a finding which
agrees with the lesser hypoactivity of ALA-D found in the
former. Since CAPD treatment seems to remove some plasma
uremic toxins more efficiently than HD [10—12], it is tempting to
speculate that it is similarly far superior than HD for removing
the plasma protein-binding ALA-D inhibitor(s).
High urea levels are not to be considered responsible for the
ALA-D inhibition ability of plasma from CRF patients. In vitro,
urea did not have any effect on this enzyme. It could be thought
that an increase of plasma porphyrins could inhibit erythrocyte
ALA-D. However, the amount of plasma porphyrin accumula-
tion in CRF is markedly lower than that observed in most
porphyria patients where ALA-D activity is normal. Further-
more, the inverse correlation between erythrocyte ALA-D
activity and plasma porphyrins was weak, and only existed
when all subjects, both patients and controls, were considered
as a single group.
As plasma and dialysate porphyrins correlated both in HD
and CAPD patients, the lower levels of plasma porphyrin found
in CAPD may be the result of a greater efficiency of this dialysis
procedure for removing porphyrins. Weekly porphyrin losses
through dialysis were threefold higher in CAPD than in HD
patients, a finding undoubtedly related to the protein losses
through peritoneal dialysis. Most (80 to 90%) plasma porphyrins
are protein-bound (to hemopexin and mainly to albumin).
Therefore, only the small free fraction of plasma porphyrins
may be filtered by HD, while CAPD can easily remove both free
and protein-bound porphyrins.
In our experience on 1532 control subjects (data not shown),
mean urinary porphyrin concentration was 76 41 gfliter
(81% coproporphyrin). Considering a mean daily urine output
of 1400 ml, a normal weekly porphyrin excretion of almost 700
tg can be estimated. In contrast, weekly porphyrin losses
through any type of dialysis (and even through residual diuresis)
in our CRF patients were very low (30 or 90 pg). Such low
values may be the consequence of either a defective or incom-
plete porphyrin filtration through the "artificial kidney" andlor
a decreased renal coproporphyrin synthesis. The kidney is not
a mere passive porphyrin filter, but an organ with an active
heme biosynthetic pathway. It is well-known that chronic renal
failure is associated with a progressive decrease of urinary
coproporphyrin excretion [21. Our patients with CRF, either on
HD or on CAPD, exhibited a profile of porphyrin "excretion"
through dialysate (or through urine, when still present) where
uroporphyrin predominated while the percentage of copropor-
phyrin was very low.
In summary, the less pronounced abnormalities in porphyrin
metabolism found in CAPD patients as compared with HD
patients are not to be considered associated to the differences in
residual renal function, in time on dialysis or in serum zinc
levels. Since CAPD is superior to HD for removing protein-
bound metabolites and uremic toxins, it is reasonable to spec-
ulate that the improvement in the anemia with the use of CAPD
may run parallel to minor abnormalities in heme biosynthetic
pathway. Further studies should be done to assess the effects of
substances such as polyamines, furancarboxylic acid, or middle
molecules, on ALA-D and other enzymes involved in hemoglo-
bin metabolism.
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